Search Results - "Follows, G"

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype by Clipson, A, Wang, M, de Leval, L, Ashton-Key, M, Wotherspoon, A, Vassiliou, G, Bolli, N, Grove, C, Moody, S, Escudero-Ibarz, L, Gundem, G, Brugger, K, Xue, X, Mi, E, Bench, A, Scott, M, Liu, H, Follows, G, Robles, E F, Martinez-Climent, J A, Oscier, D, Watkins, A J, Du, M-Q

“…To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent…”
Get full text

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib by Kazianka, L, Drucker, C, Skrabs, C, Thomas, W, Melchardt, T, Struve, S, Bergmann, M, Staber, P B, Porpaczy, E, Einberger, C, Heinz, M, Hauswirth, A, Raderer, M, Pabinger, I, Thalhammer, R, Egle, A, Wendtner, C-M, Follows, G, Hoermann, G, Quehenberger, P, Jilma, B, Jaeger, U

“…Bleeding because of impaired platelet function is a major side effect of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib. We quantitatively assessed…”
Get full text

Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: A Haematologist's Perspective by Follows, G.A

Get full text

LIMBIC ENCEPHALITIS ASSOCIATED WITH ANTIBODIES TO THE NMDA RECEPTOR IN HODGKIN LYMPHOMA by ZANDI, M. S, IRANI, S. R, FOLLOWS, G, MOODY, A. M, MOLYNEUX, P, VINCENT, A

Get full text

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1 by Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Provencio, M., Magagnoli, M., Bouabdallah, K., Heo, D. S., Diong, C. P., Munoz, J., Cao, A., Hiemeyer, F., Odongo, F., Garcia‐Vargas, J., Childs, B. H., Zinzani, P. L.

Get full text

Primary Testicular Lymphoma by Ahmad, S.S, Idris, S.F, Follows, G.A, Williams, M.V

“…Abstract Primary testicular non-Hodgkin lymphoma (PTL) comprises around 9% of testicular cancers and 1–2% of all non-Hodgkin lymphomas. Its incidence is…”
Get full text

Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage by Santarsieri, A., Mitchell, E., Sanghvi, R., Lee‐Six, H., Sturgess, K., Brice, P., Menne, T., Osborne, W., Creasey, T., Ardesnhna, K. M., Behan, S., Bhuller, K., Booth, S., Chavda, N. D., Collins, G., Culligan, D., Cwynarski, K., Davies, A., Downing, A., Dutton, D., Furtado, M., Gallop‐Evans, E., Hodson, A., Hopkins, D., Hsu, H., Iyengar, S., Jones, S. G., Linton, K. M., Lomas, O. C., Martinez‐Calle, N., Mathur, A., McKay, P., Nagumantry, S. K., Phillips, E. H., Phillips, N., Rudge, J. F., Shah, N. K., Stafford, G., Sternberg, A., Trickey, R., Uttenthal, B. J., Wetherall, N., Zhang, X., McMillan, A. K., Rahbari, R., Stratton, M., Laurenti, E., Borchmann, S., Borchmann, P., Campbell, P. J., Follows, G. A.

Get full text

Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5 by Walter, K, Cockerill, P N, Barlow, R, Clarke, D, Hoogenkamp, M, Follows, G A, Richards, S J, Cullen, M J, Bonifer, C, Tagoh, H

“…Correct hematopoietic differentiation requires the tightly regulated execution of lineage-specific and stage-restricted gene expression programs. This process…”
Get full text

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA by Santarsieri, A., Sturgess, K., Brice, P., Menne, T. F., Osborne, W., Creasey, T., Ardeshna, K. M., Behan, S., Bhuller, K., Booth, S., Collins, G. P., Cwynarski, K., Furtado, M., Iyenga, S., Jones, S. G., O'Mahony, D., Martinez‐Calle, N., McKay, P., Nagumantry, S. K., Rudge, J. F., Shah, N., Stafford, G., Sternberg, A., Uttenthal, B. J., McMillan, A. K., Follows, G. A.

Get full text

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR FOLLOW‐UP OF ELEVATE‐TN by Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Patel, K., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Fogliatto, L. M., Herishanu, Y., Banerji, V., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., Ferrant, E., Wierda, W. G., Munugalavadla, V., Yu, T., Wang, M. H., Woyach, J. A.

Get full text

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCARBAZINE SUBSTITUTION REDUCES RED CELL TRANSFUSION REQUIREMENTS AND MAY SHORTEN TIME TO MENSTRUAL PERIOD RECOVERY by Follows, G., Santarsieri, A., Sturgess, K., Menne, T., Osborne, W., Creasey, T., Ardeshna, K.M., Behan, S., Booth, S., Collins, G., Cwynarski, K., Iyengar, S., Jones, S., Martinez‐Calle, N., McKay, P., Nagumantry, S.K., O'Mahony, D., Rudge, J.F., Shah, N., Stafford, G., Sternberg, A., Uttenthal, B., McMillan, A.

Get full text

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) by Kalakonda, N., Cavallo, F., Follows, G., Goy, A., Vermaat, J., Casasnovas, O., Lavee, O., Maerevoet, M., Zijlstra, J., Bakshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J., Schuster, M., Thieblemont, C., De la Cruz, F., Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T., Warzocha, K., Oluyadi, A., McCarthy, D., Ma, X., Corona, K., Shah, J., Van Den Neste, E., Canales, M.

Get full text

Advanced Hodgkin lymphoma in the east of England cancer network: A 10‐year comparative analysis of outcomes for ABVD and escalated‐BEACOPP treated patients aged 16 to 59 by Russell, J., Collins, A., Fowler, A., Karanth, M., Saha, C., Shyamsundar, V., Docherty, S., Kirkwood, A., Maw, K., Cooke, L., Hodson, A., Shah, N., Sadullah, S., Grigoropoulos, N., Uttenthal, B., Follows, G.

Get full text

A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) by Casasnovas, R., Westin, J., Thieblemont, C., Zijlstra, J., Hill, B., De La Cruz Vicente, F., Choquet, S., Caimi, P., Kaplan, J., Canales, M., Kuruvilla, J., Follows, G., Neste, E., Meade, J., Wrigley, B., Devlin, M., Saint‐Martin, J., Nippgen, C., Gardner, H., Shacham, S., Kauffman, M., Maerevoet, M.

Get full text

Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis by GRIGOROPOULOS, N. F., SHAW, A. S., HAMPSON, F. A., BAGLIN, T. P., FOLLOWS, G. A.

Get full text

Is This the End of Radiotherapy in Early Hodgkin Lymphoma? by Maund, I.F, Williams, M.V, Hoskin, P.J, Follows, G.A

Get full text

Intermediate dose gemcitabine–cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting—a new standard of care in relapsed or refractory Hodgkin lymphoma? by Todd, T., Raj, S., Camilleri, D., Stafford, G., Bulusu, R., Follows, G., Williams, M., Marcus, R.

“…Ten percent to 20% of patients with Hodgkin Lymphoma (HL) are refractory to first-line therapy or relapse. Existing salvage regimens have response rates of…”
Get full text

Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M‐CSF (CSF‐1) receptor loci by Follows, George A., Tagoh, Hiromi, Lefevre, Pascal, Morgan, Gareth J., Bonifer, Constanze

“…The c‐FMS gene encodes the macrophage colony‐stimulating factor receptor (M‐CSFR or CSF1‐R), which is a tyrosine kinase growth factor receptor essential for…”
Get full text

Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms by BENCH, A. J., ERBER, W. N., FOLLOWS, G. A., SCOTT, M. A.

“…Summary Molecular genetic techniques have become an integral part of the diagnostic assessment for many lymphomas and other chronic lymphoid neoplasms. The…”
Get full text

PO-0737: Is there a role for hippocampal sparing consolidation radiotherapy in primary CNS lymphoma (PCNSL)? by Buckley, H., Follows, G., Ajithkumar, T.

Get full text